European specialist investor Global Healthcare Opportunities, also called GHO Capital Partners, recently announced that it has acquired Ardena — a specialist contract development and manufacturing organization focused on early phase drug development.
Financial terms of the deal, announced Jan. 9, were not disclosed. Headquartered in Belgium, Ardena assists small-to-mid-sized biopharma companies, with services spanning the full development life cycle. The company’s “Make, Analyse, File” model includes drug substance and drug product manufacturing and bioanalytical services through to regulatory dossier development.
Ardena also has sites in the Netherlands, Sweden and Latvia, with more than 300 customers in Europe, the U.S., Japan and Korea.
GHO officials plan to add to Ardena’s offerings and international footprint.
Filed Under: Drug Discovery and Development